Aviva PLC Sells 120,491 Shares of Hologic, Inc. (NASDAQ:HOLX)

Aviva PLC lowered its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 46.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 140,889 shares of the medical equipment provider's stock after selling 120,491 shares during the quarter. Aviva PLC owned 0.06% of Hologic worth $10,157,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. General Partner Inc. purchased a new stake in shares of Hologic in the fourth quarter valued at $26,000. Groupama Asset Managment boosted its position in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after acquiring an additional 2,999 shares during the period. Venturi Wealth Management LLC grew its stake in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after acquiring an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of equities research analysts have issued reports on HOLX shares. Morgan Stanley cut their target price on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Leerink Partnrs cut shares of Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Royal Bank of Canada cut their price target on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a report on Thursday, February 6th. Needham & Company LLC downgraded shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price on the stock. in a research report on Monday, February 3rd. Finally, Citigroup lowered their price objective on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $84.62.

Hologic Stock Performance

Shares of NASDAQ HOLX traded up $0.51 during trading hours on Monday, reaching $58.36. The stock had a trading volume of 562,492 shares, compared to its average volume of 1,906,974. Hologic, Inc. has a twelve month low of $56.27 and a twelve month high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The business's fifty day moving average is $62.47 and its two-hundred day moving average is $71.49. The company has a market cap of $13.10 billion, a price-to-earnings ratio of 18.41, a PEG ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.